The Short Version
The enrollment total and eligibility criteria are accurately stated. The primary trial publication, FDA review and official registry confirm that Phase 3 SURMOUNT-1 enrolled 2,539 adults without diabetes, with a BMI of at least 30, or at least 27 with at least one weight-related complication. Additional eligibility requirements do not change the accuracy of this summary.